Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Comment by goldmikeon Dec 30, 2020 11:37am
146 Views
Post# 32197400

RE:Ladies time to change your panties.

RE:Ladies time to change your panties. BetterLife Pharma (CSE: BETR)BETR is NIA's #1 overall pick for 2021. Yesterday, BETR began to breakout big and gained by $0.36 or 21.95% to close at $2 per share, its highestclosing price since becoming a psychedelic companyBETR will quickly be launching their IIS in 1Q 2021 for their Second Generation LSD product TD-0148A in preparation of their IND to launch Phase 1-2 FDA clinical trials in 3Q-4Q 2021BETR's two patents that allow for the manufacturing of TD-0148A without the need to actually make LSD puts BETR in a better position than MindMed (MMEDF). We believe BETR to be the best way to capitalize on the therapeutic potential of LSD because TD-0148A mimics the therapeutic effects of LSD without the hallucinations.BETR's patents eliminate significant regulatory controls that will be required for MMEDF if it ever begins conducting FDA trials of its own. BETR's CEOpreviously founded Merus Labs, which he took to the NASDAQ before the company was acquired in 2017 for US$270 million.
<< Previous
Bullboard Posts
Next >>